- Global Pharma News & Resources

Results From 19 Highly Anticipated Vascular Interventional Clinical Trials to Be Presented at VIVA18

Results From 19 Highly Anticipated Vascular Interventional Clinical Trials to Be Presented at VIVA18

PR Newswire

LAS VEGAS, Oct. 10, 2018

LAS VEGAS, Oct. 10, 2018 /PRNewswire/ -- Leading researchers and physicians will present results from 19 clinical trials that focus on vascular interventional technology and treatment solutions Tuesday, November 6 and Wednesday, November 7 at the VIVA Conference at Wynn Las Vegas. VIVA is an annual vascular intervention and medicine education symposium that brings together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world. Attendees include an international audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists.

The trial results and data will be presented in the Global Theater and highlighted during scheduled press conferences throughout Tuesday and Wednesday. Media outlets are invited to attend the press conferences and presentations in person; the presentations will also be available via Virtual VIVA, a live-streaming link. Press planning to attend should contact To view the detailed schedule and register to attend, visit

Clinical trial results to be released (in order of presentation):

Tuesday, November 6

IN.PACT SFA Randomized Trial 5-Year Results
John Laird Jr, MD

TOBA II Trial 1-Year Results
William Gray, MD

Stellarex DCB: Does Sex Affect Outcomes?
Maureen Kohi, MD

1-Year Outcomes for Eluvia in Long Lesions
William Gray, MD

Total IN.PACT All-Subjects Pooled 1-Year Analysis
Mehdi Shishehbor, DO, PhD

18-Month Preliminary Results From the DETOUR I Trial
Ehrin Armstrong, MD

Zilver PTX Global Data Analysis Highlights DES Benefits in Challenging Patient Populations
Michael Dake, MD

12-Month Data From the PREVEIL Early Feasibility Study
D. Christopher Metzger, MD

MIMICS-3D Registry Investigating BioMimics 3D Stent in Femoropopliteal Disease
Thomas Zeller, MD PhD

Wednesday, November 7

Lutonix® Below-the-Knee Global DCB IDE Study—Outcomes at 6 Months
Jihad Mustapha, MD

Innovative Resorbable Large Bore Closure Technology
Mike Watts, MD

2-Year Results From the SENTRY Bioconvertible IVC Filter Clinical Trial
Michael Dake, MD

PERFECT Registry: Pan-Pelvic Endovascular Intervention for Erectile Dysfunction
Tzung-Dau Wang, MD PhD

Full Cohort 12-Month Safety and Efficacy Results of the VMI-CFA Trial
Koen Deloose, MD

12-Month Results From the VENOVO Venous Stent Trial
Michael Dake, MD

Utilizing a Novel Device to Treat BTK Disease: DEEPER First-in-Man Results
John Laird Jr, MD

Utilization of the OPC to Administer Antiproliferative Medications in PAD Intervention
Pradeep K. Nair, MD

STOP-PAD Trial: JVS-100 As an Adjunct to Revascularization for Nonhealing Wounds
Mehdi Shishehbor, DO, PhD

EU Study Results of the B-Laser™
John Laird Jr, MD

About VIVA Physicians

VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, strives to be the premier educator in the field. Our team of specialists in vascular medicine, interventional cardiology, interventional radiology, and vascular surgery is driven by the passion to advance the field for optimal patient care. Educational events presented by VIVA Physicians have a distinct spirit of collegiality attained by synergizing collective talents to promote awareness and innovative therapeutic options for vascular disease worldwide. To learn more about VIVA Physicians, visit


View original content to download multimedia:

SOURCE VIVA Physicians

Editor Details

Last Updated: 10-Oct-2018